

INFORMATION DISCLOSURE STATEMENT	Docket No. 27693-1008	Application No. 09/911,703
	Applicant(s): ANDERSON, Darrell R.	Examiner: SCHWADRON, Ronald B.
	Filing Date: 7/25/2001	Group Art Unit: 1644

U.S. PATENT DOCUMENTS

Examiner Initial	REF	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE (IF APPROPRIATE)
MS	A1	4,975,278	12/4/1990	Senter et al.			
	A2	5,677,180	10/14/1997	Robinson et al.			
	A3	5,686,072	11/11/1997	Uhr et al.			
	A4	5,693,780	12/2/1997	Newman et al.			
	A5	5,721,108	2/24/1998	Robinson et al.			
	A6	5,843,398	12/1/1998	Kaminski et al.			
	A7	6,015,542	1/18/2000	Kaminski et al.			
	A8	6,090,365	7/18 /2000	Kaminski et al.			
	A9	6,120,767	9/19/2000	Robinson et al.			
	A10	6,287,537	9/11/2001	Kaminski et al.			
	A11	6,565,827	5/20/2003	Kaminski et al.			
	A12	6,652,852	11/25/2003	Robinson et al.			
	A13	6,893,625	5/17/2005	Robinson et al.			
	A14	2002-0009444	1/24/2002	Grillo-Lopez			
	A15	2003-0021781	1/30/2003	Anderson et al.			
	A16	2003-0026804	2/24/2003	Grillo-Lopez			
	A17	2003-0082172	5/1/2003	Anderson et al.			
	A18	2003-0095963	5/22/2003	Anderson et al.			
	A19	2003-0147885	8/7/2005	Anderson et al.			
	A20	2003-0206903	11/6/2003	Grillo-Lopez			
	A21	2004-0213784	10/28/2004	Grillo-Lopez et al.			
	A22	2005-0163708	7/28/2005	Robinson et al.			
	A23	2005-0186205	8/25/2005	Anderson et al.			

FOREIGN PATENT DOCUMENTS

REF	DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
						YES	NO
✓31	A24	WO 91/04320	4/4/1991	WO			X
✓21	A25	WO 93/02108	2/4/1993	WO			X

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)


MS	A26	Badger, et al. "Experimental Radioimmunotherapy of Murine Lymphoma with ¹³¹ I-labeled Anti-T-Cell Antibodies." Cancer Research, 46, pp. 6223-6228, 1986.
MS	A27	Buchsbaum, et al. "Improved Delivery of Radiolabeled Anti-B1 Monoclonal Antibody to Raji Lymphoma Xenografts by Predosing with Unlabeled Anti-B1 Monoclonal Antibody." Cancer Research; 52, pp. 637-642, 1992.


EXAMINER	DATE CONSIDERED
<i>[Signature]</i>	11/24/08
EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP Section 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	
Form PTO-A820 (also form PTO-1449) SHEET 1 OF 3	

INFORMATION DISCLOSURE STATEMENT	Docket No. 27693-1008	Application No. 09/911,703
	Applicant(s): ANDERSON, Darrell R.	Examiner: SCHWADRON, Ronald B.
	Filing Date: 7/25/2001	Group Art Unit: 1644

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

M/	A28	Biogen Idec v. Corixa Corporation, Case No. 01-1637-IEG [Doc. Nos. 635, 662, 486] (S.D. California, January 22, 2004).
	A29	Chen, et al. "Tumor Idiotypic Vaccines. VI. Synergistic Anti-Tumor Effects with Combined "Internal Image" Anti-Idiotypes and Chemotherapy." Journal of Immunology, 143, pp. 1053-1057, No. 3, 1989.
	A30	Clark et al Role of the BP35 cell surface polypeptide in human B-cell activation, Immunology Vol. 82, pp. 1766-1770, 1985.
	A31	Clark et al. "Phase I of the Anti-Bp35 Antibody Induces Human B Cell Proliferation: Implications for In Vivo Immunotherapy." Journal Cellular Biochemistry Supp. 9A, p. 63, 1985
	A32	DeNardo, et al. "Fractionated Radioimmunotherapy of B-cell Malignancies with ¹³¹ I-Lym-1." Cancer Research (Suppl.) 50, pp. 1014s-1016s, 1990.
	A33	Idec Pharmaceuticals v. Corixa Corporation, Case No. 01-1637-IEG [Doc. Nos. 486,584] (S.D. California, October 14, 2003).
	A34	Kaminski, et al. "Initial Clinical Radioimmunotherapy Results with ¹³¹ I-Anti-B1 (Anti-CD20) in Refractory B-Cell Lymphoma." Antibody Immunoconjugates, and Radiopharmaceuticals Vol. 5, No. 3 p. 345, 1992.
	A35	Kaminski, et al. " ¹³¹ I Anti-B1: Initial Clinical Evaluation in B-Cell Lymphoma." Third Conference on Rid and Rit of Cancer, Abstract. No. 144, 1990.
	A36	Langmuir, "Radioimmunotherapy: Clinical Results and Dosimetric Considerations." Nuclear Medicine Biology Vol. 19, No. 2, pp. 213-225, 1992.
	A37	Levy, et al. "Tumor Therapy with Monoclonal Antibodies." Federation Proceedings 42:9 pp. 2650-2656, 1983
	A38	Macklis, et al. "Radiobiologic Studies of Low-Dose-Rate ⁹⁰ Y-Lymphoma Therapy." Cancer Supplement, Vol. 73, No. 3, pp. 966-973, 1994.
	A39	Maloney, et al. "The Anti-Tumor effect of Monoclonal Anti-CD20 Antibody mAB) Therapy Includes Direct Anti-Proliferative Activity and Production of Apoptosis in CD20 Positive Non-Hodgkin's Lymphoma (NHL) Cell Lines." Interferon and Chronic Myelogenous Leukemia." Fred Hutchinson Cancer Research & University of Washington, 637a, p. 2535


EXAMINER	DATE CONSIDERED
	1/24/08
EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP Section 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	
Form PTO-A820 (also form PTO-1449) SHEET 2 OF 3	




INFORMATION DISCLOSURE STATEMENT	Docket No. 27693-1008	Application No. 09/911,703
	Applicant(s): ANDERSON, Darrell R.	Examiner: SCHWADRON, Ronald B.
	Filing Date: 7/25/2001	Group Art Unit: 1644

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

271	A40	Maloney, et al. "Monoclonal Anti-Idiotyp Antibody Therapy of B-Cell Lymphoma: The Addition of a Short Course of Chemotherapy Does Not Interfere with the Antitumor Effect Nor Prevent the Emergence of Idiotyp-Negative Variant Cells." Blood, Vol. 80, No. 6, pp. 1502-1510, 1992.
	A41	Masucci, et al. "Chemotherapy and Immunotherapy of Colorectal Cancer." Medical Oncology Tumor Pharmacother Vol. 8, No. 3, pp. 207-220, 1991.
	A42	Nadler, et al. "A Unique Cell Surface Antigen Identifying Lymphoid Malignancies of B Cell Origin." Journal of Clinical Investigative, Vol. 67, pp. 134-140, 1981.
	A43	Reilly, "Radioimmunotherapy of malignancies." Clinical Pharmacy, Vol. 10, pp. 359-375, 1991.
	A44	Press, et al. Scientific Proceedings, ASCO, Abstract No. 864, 1986.
	A45	See-Lasley, et al. "HODGKIN'S DISEASE AND NON-HODGKIN'S LYMPHOMA Nitrogen mustard, vincristine (Oncovin), procarbazine, and prednisone (MOPP)." Manual of Oncology Therapeutics, C.V. Mosby Company, pp. 44-71, 1981.
	A46	Senter, et al. "Enhancement of the <i>in vitro</i> and <i>in vivo</i> Antitumor Activities of Phosphorylated Mitomycin C and Etoposide Derivatives by Monoclonal Antibody-Alkaline Phosphatase Conjugates." Cancer Research 49, pp. 5789-5792, 1989.
✓	A47	Stashenko, et al. "Characterization of Human B Lymphocyte-Specific Antigen." The Journal of Immunology Vol. 125, No. 4, pp. 1678-1685, 1960: 1989

EXAMINER 	DATE CONSIDERED 11/28/08
EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP Section 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	
Form PTO-A820 (also form PTO-1449) SHEET 3 OF 3	




INFORMATION DISCLOSURE STATEMENT	Docket No. 27693-01008	Application No. 09/911,703
	Applicant(s): ANDERSON, Darrell A.	Examiner: SCHWADRON, Ronald B.
	Filing Date: 7/25/2001	Group Art Unit: 1644

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

WMS	B1	Chinn, et al. "Production and characterization of radiolabeled anti-CD20 monoclonal antibody: potential application to treatment of B-cell lymphoma." Proceedings of the American Medical Association for Cancer Research, Volume 33, Abstract 1012, p. 337, 1992.
	B2	Classon, et al. "The Primary Structure of the Human Leukocyte Antigen CD37, A Species Homologue of the Rat MRC OC-44 Antigen." The Journal of Experimental Medicine, Volume 169, No. 4, pp. 1497-1502, 1989.
	B3	DeNardo, et al. "Requirements for a Treatment Plan in System for Radioimmunotherapy." International Journal of Radiation Oncology Biology Physics, Volume 11, Number 2, pp. 335-348, 1985.
	B4	Kaminski, et al. "Radioimmunotherapy (RIT) of Refractory B-Cell Lymphoma with ¹³¹ I-Anti-B1 (Anti-CD20) Antibody: Promising Early Results Using Non-Marrow Ablative Radiation Doses." Blood, Abstract 161, p. 162,
	B5	Langmuir, "Radiomunotherapy: Clinical Results and Dosimetric Considerations." Nuclear Medicine and Biology, Volume 19, Number 2, pp. 213-225, 1992.
	B6	Larson, et al. "Comparison of Bone Marrow Dosimetry and Toxic Effect of High Dose ¹³¹ I-labeled Monoclonal Antibodies Administered to Man." Nuclear Medicine and Biology, Volume 16, No. 2, pp.153-158, 1989.
	B7	Leichner, et al. "Tumor dosimetry in radioimmunotherapy: Methods of calculation for beta particles." Medical Physics, Volume 20, Number 2, Pt.2, pp. 529-534, 1993
	B8	Leichner, et al. "Dosimetry and Treatment Planning in Radioimmunotherapy." Frontiers of Radiation Therapy and Oncology, Vol. 24, pp. 109-120, 1990.
	B9	Link, et al. "A Unique Antigen on Mature B-Cells Defined by a Monoclonal Antibody." The Journal of Immunology, Vol. 137, No. 9, pp. 3013-3018, 1986.
	B10	Macey, et al. "A Treatment Planning Program for Radioimmunotherapy" Frontiers of Radiation Therapy and Oncology, Vol. 24, pp. 123-131, 1990.
	B11	Meredith, et al. "Dose Fractionation of Radiolabeled Antibodies in Patients with Metastatic Colon Cancer." Journal of Nuclear Medicine, Volume 33, Number 9, pp. 1648-1653, 1992.


EXAMINER	DATE CONSIDERED 11/24/08
EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP Section 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	
Form PTO-A820 (also form PTO-1449) SHEET 1 OF 2	



INFORMATION DISCLOSURE STATEMENT	Docket No. 27693-01008	Application No. 09/911,703
	Inventor(s): ANDERSON, Darrell A.	Examiner: SCHWADRON, Ronald B.
	Filing Date: 7/25/2001	Group Art Unit: 1644

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

W31	B12	Parker, et al. "Radioimmunotherapy of Human B-Cell Lymphoma with ⁹⁰ Y-conjugated Antiidiotype Monoclonal Antibody." Cancer Research, Volume 50, No. 3, pp. 1022s-1028s, 1990.
	B13	Pearson, et al. "Enhanced Therapeutic Efficacy of an Immunotoxin in combination with Chemotherapy against an Intraperitoneal Human Tumor Xenograft in Athymic Mice." Cancer Research Volume 49, No. 18, pp. 4990-4995, 1989.
	B14	Press, et al. "Endocytosis and Degradation of Monoclonal of Antibodies Targeting Human B-Cell Malignancies" Cancer Research, Volume 49, No. 17, pp. 4906-4912, 1989.
	B15	Press, et al. "Radiolabeled Antibody Therapy of Human B Cell Lymphomas." Immunobiology of Proteins and Peptides VI, Volume 303, pp. 91-96, 1991.
	B16	Securities and Exchange Commission, Form S-1 Registration Statement, Filed 1991, IDEC Pharmaceuticals
	B17	Senter, Peter D. "Activation of prodrugs by antibody-enzyme conjugates: a new approach to cancer therapy." The FASEB Journal, Vol. 4. pp. 188-193, 1990.
	B18	Senter, et al. "Activation of Prodrugs by Antibody-Enzyme Conjugates" Immunobiology of Proteins and Peptides VI, Volume 303, pp. 97-105, 1991.
	B19	Schwartz-Albiez, et al. "The B Cell-Associated CD37 Antigen (gp40-52) Structure and Subcellular Expression of an Extensively Glycosylated Glycoprotein." The Journal of Immunology, Vol. 140, No. 3, pp. 905-914, 1988.
	B20	Sharkey, et al. "Biological Considerations for Radioimmunotherapy." Cancer Research, Volume 50, No. 3, pp. 964s-969s, pp. 1990.
	B21	Stewart, et al. "Intraperitoneal ¹³¹ I- And ⁹⁰ Y-Labelled Monoclonal Antibodies for Ovarian Cancer: Pharmacokinetics and Normal Tissue Dosimetry." International Journal of Cancer, Supplement 3, pp. 71-76, 1988.
	B22	Uckun, et al. "Combined Ex Vivo Treatment with Immunotoxins and Mafosfamid: A Novel Immunochemotherapeutic Approach for Elimination of Neoplastic T Cells from Autologous Marrow Grafts." The Journal of Immunology, Vol. 134, No. 5, pp. 3504-3515, 1985.
	B23	Uckun, et al. "Increased Efficiency in Selective Elimination of Leukemia Cells by a Combination of a Stable Derivative of Cyclophosphamide and a Human B-Cell-specific Immunotoxin Containing Pokeweed Antiviral Protein." Cancer Research , Volume 45, No. 1, pp. 69-75, 1985.
✓	B24	Yokota, et al. "Synergistic Potentiation of in Vivo Antitumor Activity of Anti-Human T-Leukemia Immunotoxins by Recombinant α-Interferon and Daunorubicin." Cancer Research, Volume 50, No. 1, pp. 32-37, 1990.


EXAMINER 	DATE CONSIDERED 11/24/08
---	---------------------------------

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP Section 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Form PTO-A820 (also form PTO-1449)

SHEET 2 OF 2

INFORMATION DISCLOSURE STATEMENT	Docket No. 27693-01008	Serial No: 09/ 911,703
	Inventor(s): D.R. Anderson <i>et al.</i>	Examiner: R. Schwadron
	Filed: 25 July 2001	Art Unit: 1644



OTHER PATENT DOCUMENTS

INITIAL	INDEX	CITATION	PATENTEE OR APPLICANT	T
M1	D1	WO 94/11026	IDEC PHARMACEUTICALS CORP.	

EXAMINER SIGNATURE	DATE CONSIDERED 1/27/08
Initial if a citation is considered, whether or not citation is in conformance with MPEP § 609. Draw line through citation if not in conformance and not considered. Include a copy of this form with the next communication to applicant.	
Form PTO-1449 (modified)	SHEET 1 OF 1